Phase II clinical study of TY-0305 in symptomatic patients with hypertrophic obstructive cardiomyopathy -A pilot study-
Phase 2
Completed
- Conditions
- Symptomatic hypertrophic obstructive cardiomyopathy
- Registration Number
- jRCT2080224827
- Lead Sponsor
- TOA EIYO LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
(1) Patients with New York Heart Association (NHYA) functional class II or III. (2) Patients able to perform the cardiopulmonary exercise test.
Exclusion Criteria
(1) Patients with past or current medical history of persistent ventricular tachycardia or ventricular fibrillation. (2) Patients with persistent or permanent atrial fibrillation. (3) Patients with past or current medical history of coronary artery disease.
Study & Design
- Study Type
- Interventional
- Study Design
- Multicenter, single-arm, open-label study
- Primary Outcome Measures
Name Time Method - efficacy
Peak oxygen uptake
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does TY-0305 target in hypertrophic obstructive cardiomyopathy patients?
How does TY-0305 compare to beta-blockers and calcium channel blockers in managing HOCM symptoms?
Are there specific biomarkers that identify HOCM patients likely to respond to TY-0305 therapy?
What adverse events are associated with TY-0305 in phase II trials for cardiomyopathy?
What other compounds or combination therapies are being explored for symptomatic HOCM treatment?
Trial Locations
- Locations (1)
Japan
Location not specified
Japan